I-Corps: A cloud-based searchable catalog to link geographically and population diverse patient genomic, phenotypic and clinical data

这个i-Corps项目的更广泛的影响/商业潜力是开发一个基于云的可搜索目录，以提供对全球患者数据的访问，这些数据可用于为患者提供更好的治疗。目前，有许多问题需要链接和分析患者数据的能力。问题是，目前使用的大多数患者数据来自北欧同样少数几个缺乏地理或人口多样性的机构。其结果是，患者数据在与非北欧人群相关的问题上的用途有限。正在开发的患者数据集将允许学术和商业机构提出问题，将来自世界各地的患者数据联系起来，以获得适用于所有患者群体的答案。这些数据将提供给治疗患者的医生，以确保更准确的治疗和药物处方。这些数据还将使研究机构和商业企业能够通过缩短临床试验来开发药物并加快其上市速度。I-Corps项目的基础是开发一个单一的基于云的、可搜索的数据目录，其中包含来自不同地理位置的人群的患者基因组、表型和临床数据，以及一个可以分析数据的研究环境。使用来自不同地理位置的患者群体的患者数据的能力将允许高度精确地确定针对患者的治疗，不仅适用于具有北欧背景的患者，而且适用于世界各地的患者。学术和商业机构将能够改进他们的研究并加快结果，方法是分析来自不同地区的患者数据，在几个小时或几天内回答问题，目前需要数年时间。它将允许商业机构加快治疗研究和简化临床试验。其结果将是更多的药物在更短的时间内以更少的资金通过对更多疾病的临床试验。患者数据集还将允许商业机构使用来自不同地理位置的基因分析来发现患有罕见疾病的患者，而不是目前基于医生确定的预后进行推断的做法。其目标是在使用患者数据的情况下改进医学研究和患者治疗。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is to develop a cloud-based, searchable catalog to provide access to global patient data that can be used to provide improved treatments for patients. Currently, there are many questions that require the ability to link and analyze patient data. The problem is that the majority of patient data currently used comes from the same few institutions in Northern Europe that lack geographic or population diversity. The result is that the patient data has limited use for questions related to populations that do not derive from Northern Europe. The patient dataset under development will allow academic and commercial institutions to ask questions that link patient data from around the world to get answers that are applicable to all patient populations. The data will be available to physicians treating patients to ensure more precise treatments and prescription of drugs. The data also will allow research institutions and commercial enterprises to develop drugs and speed their delivery to market by shortening clinical trials. This I-Corps project is based on the development of a single cloud-based, searchable data catalog containing patient genomic, phenotypic and clinical data from geographically diverse populations and a research environment within which the data can be analyzed. The ability to use patient data from geographically diverse patient populations will allow for the ability to determine patient-specific treatments with a high degree of precision, not just for those with a Northern European background, but patients everywhere. Academic and commercial institutions will be able to improve their research and expedite results by analyzing patients' data from geographically diverse regions to answer questions in a few hours or days that currently takes years. It will allow commercial institutions to expedite therapeutic research and streamline clinical trials. The result will be more drugs making it through clinical trials for more diseases in a shorter time for less money. The patient data set also will allow commercial institutions to find patients with rare diseases using genetic analysis from different geographies, instead of the current practice of extrapolating based on a doctor-determined prognosis. The goal is to improve medical research and patient treatment where patient data is used.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.